Percheron Therapeutics Limited

—As of Sun 8 Nov 2026, 12:00 UTC
ASX:PERHealthcare
Country Australia
PE (Fwd) •••
TSR 10Y CAGR (21.60%)
Div yield —
ROE (54.66%)
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.99
PE TTM —
TSR TTM (55.08%)
Mkt cap A$6.938M
ROIC (33.95%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.0043
23.31%
(88.14%)
Sell 0|8|2|12|8
2Q26
3Q26
4Q26
1Q27
Earnings per share$
—
—
—
—
26.99%
23.97%
12.14%
3.66%
Revenue$M
0.716
0.744
0.787
0.825
7.39%
8.58%
10.48%
12.68%
Peers (US$4.085M)
Cap (US$)
PE
5.345M
148.1x
4.921M
—
Capital
TTM
5Y
10Y
Leveragex
0.954
0.781
0.685
EBIT/Intx
0.908
0.238
0.236
Own earn%
(9.12)
(27.88)
(26.00)
Sh yield%
18.82
28.67
30.54
Owners
Insiders/Inst%
6.01
76.63
Short interest%
5.78
SBC / revenue%
5.47
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
17
Op margin range%
3–8
$1 testx
—
Incr. ROIC%
14